BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37716979)

  • 41. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
    Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
    Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
    [TBL] [Abstract][Full Text] [Related]  

  • 42. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Knockdown of long noncoding RNA colorectal neoplasia differentially expressed inhibits hepatocellular carcinoma progression by mediating the expression of nuclear autoantigenic sperm protein.
    Zhu Y; Li B; Xu G; Han C; Xing G
    Oncol Rep; 2021 Dec; 46(6):. PubMed ID: 34633056
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines.
    Gong J; Chen Y; Yang L; Pillai R; Shirasawa S; Fakih M
    Anticancer Res; 2017 Jun; 37(6):2831-2838. PubMed ID: 28551618
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer.
    He Z; Thorrez L; Siegfried G; Meulemans S; Evrard S; Tejpar S; Khatib AM; Creemers JWM
    Oncogene; 2020 Apr; 39(17):3571-3587. PubMed ID: 32139876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
    Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH
    Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
    Ye H; Liu Y; Wu K; Luo H; Cui L
    Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dual role of sprouty2 as an inhibitor of RAS/ERK-driven proliferation and a promoter of cancer invasion in KRAS wild-type colorectal cancer.
    Lee CT; Chu CA; Wang YM; Wang YW; Chen YL; Ho CL; Yeh YM; Lin PC; Lin BW; Chen PC; Chen SH; Chan RH; Chang C; Chow NH
    Mol Carcinog; 2023 Jul; 62(7):951-962. PubMed ID: 37014154
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer.
    Yokota T; Shibata N; Ura T; Takahari D; Shitara K; Muro K; Yatabe Y
    Transl Res; 2010 Aug; 156(2):98-105. PubMed ID: 20627194
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DNA methylation-regulated and tumor-suppressive roles of miR-487b in colorectal cancer via targeting MYC, SUZ12, and KRAS.
    Chen X; Lin ZF; Xi WJ; Wang W; Zhang D; Yang F; Li YF; Huo Y; Zhang TZ; Jiang YH; Qin WW; Yang AG; Wang T
    Cancer Med; 2019 Apr; 8(4):1694-1709. PubMed ID: 30791232
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
    Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
    Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modulating Pluripotency Network Genes with Omega-3 DHA is followed by Caspase- 3 Activation and Apoptosis in DNA Mismatch Repair-Deficient/KRAS-Mutant Colorectal Cancer Stem-Like Cells.
    Mahmoudi N; Delirezh N; Sam MR
    Anticancer Agents Med Chem; 2020; 20(10):1221-1232. PubMed ID: 32116204
    [TBL] [Abstract][Full Text] [Related]  

  • 53. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
    Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased expression of the long noncoding RNA CRNDE-h indicates a poor prognosis in colorectal cancer, and is positively correlated with IRX5 mRNA expression.
    Liu T; Zhang X; Yang YM; Du LT; Wang CX
    Onco Targets Ther; 2016; 9():1437-48. PubMed ID: 27042112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa.
    Jafari M; Laraqui A; Baba W; Benmokhtar S; Zaitouni SE; Ali AA; Bounaim A; Moujahid M; Tanz R; Mahfoud T; Sbitti Y; Annaz HE; Abi R; Tagajdid MR; Kochri SE; Lahlou IA; Hsaini HE; Belayachi L; Benjouad A; Ichou M; En-Nya A; Ennibi K
    BMC Cancer; 2022 Nov; 22(1):1142. PubMed ID: 36344948
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology.
    László L; Kurilla A; Takács T; Kudlik G; Koprivanacz K; Buday L; Vas V
    Cells; 2021 Mar; 10(3):. PubMed ID: 33802849
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 58. HNRNPA2B1-mediated m
    Li K; Gong Q; Xiang XD; Guo G; Liu J; Zhao L; Li J; Chen N; Li H; Zhang LJ; Zhou CY; Wang ZY; Zhuang L
    J Transl Med; 2023 Jun; 21(1):382. PubMed ID: 37308993
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship Between 18F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level.
    Lee JH; Kang J; Baik SH; Lee KY; Lim BJ; Jeon TJ; Ryu YH; Sohn SK
    Medicine (Baltimore); 2016 Jan; 95(1):e2236. PubMed ID: 26735530
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.
    Tarpgaard LS; Ørum-Madsen MS; Christensen IJ; Nordgaard C; Noer J; Guren TK; Glimelius B; Sorbye H; Ikdahl T; Kure EH; Tveit KM; Nielsen HJ; Pfeiffer P; Brünner N; Moreira JM
    Oncotarget; 2016 Sep; 7(37):59441-59457. PubMed ID: 27509063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.